Collectively, these results revealed that DDX5 is a critical therapeutic target in CML and that FL118 is an effective candidate compound for the treatment of BCR-ABL inhibitor-resistant CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.